Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias

Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism of action is neuroprotective and potentially therapeutic in several neuropsychiatric diseases. It has been approved by the FDA for the treatment of moderate to severe Alzheimer’s disease (AD) either as a monotherapy or in combination with cholinesterase inhibitors. This review covers key studies of memantine’s safety and efficacy in treating moderate to severe AD. It also covers current research into other dementias including but not exclusively mild AD and vascular dementia. Other studies on the efficacy of memantine for other neuropsychiatric diseases are discussed. Memantine is a safe and effective drug that merits further research on several topics. Clinicians should be aware of new studies and potential uses of memantine because of its safety and efficacy.

[1]  J. W. COOK,et al.  “The Merck Index” , 1953, Nature.

[2]  P. Fischer,et al.  [Effects of intravenous administration of memantine in parkinsonian patients (author's transl)]. , 1977, Arzneimittel-Forschung.

[3]  R. Clemens,et al.  [Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study]. , 2008, Deutsche medizinische Wochenschrift.

[4]  C. Cotman,et al.  β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage , 1990, Brain Research.

[5]  S. Warach,et al.  Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[6]  G. Zeevalk,et al.  Evidence that the Loss of the Voltage‐Dependent Mg2+ Block at the N‐Methyl‐D‐Aspartate Receptor Underlies Receptor Activation During Inhibition of Neuronal Metabolism , 1992, Journal of neurochemistry.

[7]  S. Lipton,et al.  Delayed administration of memantine prevents N‐methyl‐D‐aspartate receptor‐mediated neurotoxicity , 1993, Annals of neurology.

[8]  S. L. Mobley,et al.  MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. , 1995, European journal of pharmacology.

[9]  S. Lipton,et al.  Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Lipton,et al.  Transcriptional or translational inhibition blocks low dose NMDA-mediated cell death , 1995, Neuroreport.

[11]  G. Collingridge,et al.  Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells , 1996, British journal of pharmacology.

[12]  S. Lipton,et al.  Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. , 1996, Investigative ophthalmology & visual science.

[13]  S. Lipton,et al.  Molecular basis of glutamate toxicity in retinal ganglion cells , 1997, Vision Research.

[14]  H S Chen,et al.  Mechanism of memantine block of NMDA‐activated channels in rat retinal ganglion cells: uncompetitive antagonism. , 1997, The Journal of physiology.

[15]  S. Lipton,et al.  Calcium, free radicals and excitotoxins in neuronal apoptosis. , 1998, Cell calcium.

[16]  S. Lipton,et al.  Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. , 1999, European journal of pharmacology.

[17]  M. Merello,et al.  Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. , 1999, Clinical neuropharmacology.

[18]  B. Winblad,et al.  Memantine in severe dementia: results of the 9M‐best study (benefit and efficacy in severly demented patients during treatment with memantine) , 1999, International journal of geriatric psychiatry.

[19]  Memantine (a N-Methyl-d-Aspartate Receptor Antagonist) in the Treatment of Neuropathic Pain After Amputation or Surgery: A Randomized, Double-Blinded, Cross-Over Study , 2000, Anesthesia and analgesia.

[20]  J Korf,et al.  β‐Amyloid neurotoxicity is mediated by a glutamate‐triggered excitotoxic cascade in rat nucleus basalis , 2000, The European journal of neuroscience.

[21]  R. Dempsey,et al.  Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats , 2001, Brain Research.

[22]  P. Popik,et al.  The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans , 2001, Psychopharmacology.

[23]  C. Parsons,et al.  The N-methyl-d-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner , 2001, Neuroscience Letters.

[24]  M. Max,et al.  Dextromethorphan and Memantine in Painful Diabetic Neuropathy and Postherpetic Neuralgia: Efficacy and Dose-Response Trials , 2002, Anesthesiology.

[25]  Efficacy and Safety of Memantine in Patients With Mild to Moderate Vascular Dementia: A Randomized, Placebo-Controlled Trial (MMM 300) , 2002, Stroke.

[26]  A. Stöffler,et al.  Memantine in Vascular Dementia , 2003, International Psychogeriatrics.

[27]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[28]  P. Schwenkreis,et al.  Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain – results of a randomized double-blinded, placebo-controlled trial , 2003, Pain.

[29]  E. Sofić,et al.  A placebo-controlled study of memantine (Ebixa) in dementia of Wernicke-Korsakoff syndrome. , 2003, Medicinski arhiv.

[30]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[31]  C. Braun,et al.  A Placebo-Controlled Randomized Crossover Trial of the N-Methyl-d-Aspartic Acid Receptor Antagonist, Memantine, in Patients with Chronic Phantom Limb Pain , 2004, Anesthesia and analgesia.

[32]  M. Gerlach,et al.  The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. , 2004, Journal of neural transmission. Supplementum.

[33]  B. Rive,et al.  Memantine enhances autonomy in moderate to severe Alzheimer's disease , 2004, International journal of geriatric psychiatry.

[34]  CarstenCulmsee,et al.  Combination Therapy in Ischemic Stroke: Synergistic Neuroprotective Effects of Memantine and Clenbuterol , 2004 .

[35]  S. Gauthier,et al.  Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies , 2005, International journal of geriatric psychiatry.

[36]  M. Rossor,et al.  Delusions and hallucinations in dementia with Lewy bodies: Worsening with memantine , 2005, Neurology.

[37]  S. Vosburg,et al.  An evaluation of the reinforcing effects of memantine in cocaine-dependent humans. , 2005, Drug and alcohol dependence.

[38]  Ann Marie Hake,et al.  The use of memantine in dementia with Lewy bodies. , 2005, Journal of Alzheimer's disease : JAD.

[39]  Steven G Potkin,et al.  Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[40]  S. Lipton.  Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond , 2006, Nature Reviews Drug Discovery.

[41]  B. Reisberg,et al.  A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. , 2006, Archives of neurology.

[42]  P. Toth,et al.  In vitro galantamine-memantine co-application: Mechanism of beneficial action , 2006, Neuropharmacology.

[43]  D. Luckenbaugh,et al.  A double-blind, placebo-controlled study of memantine in the treatment of major depression. , 2006, The American journal of psychiatry.

[44]  P. Lapchak.  Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits , 2006, Brain Research.

[45]  J. Gunstad,et al.  Clock Drawing and Frontal Lobe Behavioral Effects of Memantine in Alzheimer’s Disease: A Rater-Blinded Study , 2007, American journal of Alzheimer's disease and other dementias.

[46]  J. Olin,et al.  A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[47]  Changlian Zhu,et al.  Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity , 2006, The European journal of neuroscience.

[48]  Pierre N Tariot,et al.  Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment , 2006, Neurology.

[49]  P. Dautzenberg,et al.  Observations from a 14-week open-label trial with memantine suggest variable response on behavioral symptoms and cognition, depending on former treatment of AD , 2006, International Psychogeriatrics.

[50]  J. Olin,et al.  Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving Donepezil: An Exploratory Reanalysis , 2006, Alzheimer disease and associated disorders.

[51]  J. Kornhuber,et al.  Memantine fails to facilitate partial cigarette deprivation in smokers – no role of Memantine in the treatment of nicotine dependency? , 2007, Journal of Neural Transmission.

[52]  B. Ott,et al.  Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease , 2007, Journal of Neurology.

[53]  J. Olin,et al.  Activities of Daily Living in Moderate-to-Severe Alzheimer Disease: An Analysis of the Treatment Effects of Memantine in Patients Receiving Stable Donepezil Treatment , 2006, Alzheimer disease and associated disorders.

[54]  R. Findling,et al.  A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. , 2007, Journal of child and adolescent psychopharmacology.

[55]  Irene Gottlob,et al.  Congenital nystagmus: Randomized, controlled, double‐masked trial of memantine/gabapentin , 2007, Annals of neurology.

[56]  M. Riepe,et al.  Domain-Specific Improvement of Cognition on Memantine in Patients with Alzheimer’s Disease Treated with Rivastigmine , 2007, Dementia and Geriatric Cognitive Disorders.

[57]  W. Ondo,et al.  A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. , 2007, Parkinsonism & related disorders.

[58]  J. Roh,et al.  Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage , 2007, Neuroscience Letters.

[59]  S. Lipton,et al.  Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study , 2007, AIDS.

[60]  L. Schneider,et al.  A double‐blind, placebo‐controlled trial of memantine in age‐associated memory impairment (memantine in AAMI) , 2007, International journal of geriatric psychiatry.

[61]  D. Wilkinson,et al.  Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease , 2007, Dementia and Geriatric Cognitive Disorders.

[62]  H. Niederhofer.  Glutamate antagonists seem to be slightly effective in psychopharmacologic treatment of autism. , 2007, Journal of clinical psychopharmacology.

[63]  J. Ferguson,et al.  An Open-label, Flexible-Dose Study of Memantine in Major Depressive Disorder , 2007, Clinical neuropharmacology.

[64]  N. Birbaumer,et al.  Continuous brachial plexus blockade in combination with the NMDA receptor antagonist memantine prevents phantom pain in acute traumatic upper limb amputees , 2007, European journal of pain.

[65]  L. Schneider,et al.  Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials , 2007, The Lancet Neurology.

[66]  N. Birbaumer,et al.  Memantine Treatment of Complex Regional Pain Syndrome: A Preliminary Report of Six Cases , 2007, The Clinical journal of pain.

[67]  P. Tariot,et al.  A 24-week Randomized, Controlled Trial of Memantine in Patients With Moderate-to-severe Alzheimer Disease , 2007, Alzheimer disease and associated disorders.

[68]  M. Chez,et al.  Memantine as Adjunctive Therapy in Children Diagnosed With Autistic Spectrum Disorders: An Observation of Initial Clinical Response and Maintenance Tolerability , 2007, Journal of child neurology.

[69]  S. Strakowski,et al.  Memantine normalizes brain activity in the inferior frontal gyrus: A controlled pilot fMRI study , 2007, Schizophrenia Research.

[70]  Roy W Jones,et al.  Safety and tolerability of once‐daily versus twice‐daily memantine: a randomised, double‐blind study in moderate to severe Alzheimer's disease , 2007, International journal of geriatric psychiatry.

[71]  M. Haney,et al.  The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. , 2007, Experimental and clinical psychopharmacology.

[72]  S. Evans,et al.  A pilot double-blind treatment trial of memantine for alcohol dependence. , 2007, Alcoholism, clinical and experimental research.

[73]  Roy W Jones,et al.  Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials , 2007, Dementia and Geriatric Cognitive Disorders.

[74]  H. Khouzam,et al.  Pilot Trial of Memantine in the Treatment of Posttraumatic Stress Disorder , 2007, Psychiatry.

[75]  J. Lönnqvist,et al.  Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication , 2008, Substance abuse treatment, prevention, and policy.

[76]  A. Atri,et al.  Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease , 2008, Alzheimer disease and associated disorders.

[77]  F. Gonzalez-Lima,et al.  Neuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenone , 2008, Brain Research.

[78]  P. Mecocci,et al.  Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. , 2008, Journal of Alzheimer's disease : JAD.

[79]  S. Tepper,et al.  Memantine in the Preventive Treatment of Refractory Migraine , 2008, Headache.

[80]  J. Olin,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. , 2008, Current Alzheimer research.

[81]  B. Langguth,et al.  Tinnitus treatment with memantine , 2008, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[82]  W. Danysz,et al.  Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats , 2008, Behavioural pharmacology.

[83]  Hans Förstl,et al.  A 6‐month, open‐label study of memantine in patients with frontotemporal dementia , 2008, International journal of geriatric psychiatry.

[84]  O. Levin,et al.  [Efficacy and safety of memantine in dementia with Lewy bodies]. , 2008, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[85]  M. Araie,et al.  Memantine Protects Against Secondary Neuronal Degeneration in Lateral Geniculate Nucleus and Superior Colliculus after Retinal Damage in Mice , 2008, CNS neuroscience & therapeutics.

[86]  Levin Os,et al.  Efficacy and safety of memantine in dementia with Lewy bodies , 2008 .

[87]  Abraham Weizman,et al.  Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study , 2008, European Neuropsychopharmacology.

[88]  S. Bakchine,et al.  Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. , 2008, Journal of Alzheimer's disease : JAD.

[89]  J. Lönnqvist,et al.  Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. , 2008, The Journal of clinical psychiatry.

[90]  B. P. Brennan,et al.  Memantine in the treatment of binge eating disorder: an open-label, prospective trial. , 2008, The International journal of eating disorders.

[91]  C. Ballard,et al.  Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. , 2008, The Journal of clinical psychiatry.

[92]  S. Gauthier,et al.  Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis , 2008, International journal of geriatric psychiatry.

[93]  G. Waldemar,et al.  Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease , 2008, International journal of geriatric psychiatry.

[94]  T. Voronina,et al.  [Features of memantine action profile in cholinergic deficit and intracerebral posttraumatic hematoma (hemorrhagic stroke) models in rats]. , 2008, Eksperimental'naia i klinicheskaia farmakologiia.

[95]  G. Grossberg,et al.  Memantine Therapy of Behavioral Symptoms in Community-Dwelling Patients with Moderate to Severe Alzheimer’s Disease , 2009, Dementia and Geriatric Cognitive Disorders.

[96]  J. Becker,et al.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[97]  Chunhua Liu,et al.  Neuroprotective effect of memantine combined with topiramate in hypoxic–ischemic brain injury , 2009, Brain Research.

[98]  J. Roh,et al.  Augmentation of nitrite therapy in cerebral ischemia by NMDA receptor inhibition. , 2009, Biochemical and biophysical research communications.

[99]  C. Yiannoutsos,et al.  A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy , 2006, Journal of NeuroVirology.

[100]  S. Roth,et al.  Clinical Interventions in Aging , 2022 .